NEW YORK (GenomeWeb News) – Illumina said today that its noninvasive prenatal testing subsidiary Verinata Health has signed an exclusive agreement with Teva Pharmaceutical Industries to commercialize its Verifi test in Israel.

Under the terms of the five-year agreement, Teva will be the exclusive distributor of Verifi in Israel. All tests will be run in Verinata's CLIA-certified laboratory in California, while Israel's Clalit Health Services will provide reimbursement for Verifi through supplemental insurance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.